Why the study?
The cost-effectiveness of percutaneous coronary intervention for ischemic heart disease in Japan was undetermined.
Is percutaneous coronary intervention cost-effective compared with medical therapy for ischemic heart disease in Japan?
Is percutaneous coronary intervention cost-effective compared with medical therapy for ischemic heart disease in Japan?
Answers are grounded in this paper and cite their sources.
PCI is highly cost-effective for STEMI in Japan, and FFR-guided PCI may be cost-effective for symptomatic angina pectoris, but it is not cost-effective for asymptomatic patients.
BACKGROUND: The cost-effectiveness of percutaneous coronary intervention (PCI) for ischemic heart disease is undetermined in Japan. The aim of this study was to analyze the cost-effectiveness of PCI compared with medical therapy for ST-elevation myocardial infarction (STEMI) and angina pectoris (AP) in Japan. METHODS AND RESULTS: We used Markov models for STEMI and AP to assess the costs and benefits associated with PCI or medical therapy from a health system perspective. We estimated the incremental cost-effectiveness ratio (ICER), expressed as quality-adjusted life-years (QALY), and ICER <¥5 m per QALY gained was judged to be cost-effective. The impact of PCI on cardiovascular events was based on previous publications. In STEMI patients, the ICER of PCI over medical treatment was ¥0.97 m per QALY gained. The cost-effectiveness probability of PCI was 99.9%. In AP patients, the ICER of fractional flow reserve (FFR)-guided PCI over medical treatment was ¥4.63 m per QALY gained. The cost-effectiveness probability of PCI was 50.4%. The ICER of FFR-guided PCI for asymptomatic patients was ¥23 m per QALY gained. CONCLUSIONS: In STEMI patients, PCI was cost-effective compared with medical therapy. In AP patients, FFR-guided PCI for symptomatic patients could be cost-effective compared with medical therapy. FFR-guided PCI for asymptomatic patients with myocardial ischemia was not cost-effective.
No takes yet. Share an insight, caveat, or question.
Kodera et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: